NeuroPace to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 18, 2024 16:05 ET
|
NeuroPace, Inc.
MOUNTAIN VIEW, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced...
NeuroPace to Host Investor Day on January 28th in New York City
December 12, 2024 16:05 ET
|
NeuroPace, Inc.
MOUNTAIN VIEW, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced...
NeuroPace to Showcase the RNS System at the 2024 American Epilepsy Society (AES) Annual Meeting
December 04, 2024 16:05 ET
|
NeuroPace, Inc.
RNS System to be featured in over 70 scientific presentations and posters Pre-book a demonstration in the NeuroPace Tech Suite to see the latest innovations of the RNS System which simplify the...
NeuroPace Completes Enrollment in Feasibility Study of RNS System for Lennox-Gastaut Syndrome
December 03, 2024 16:05 ET
|
NeuroPace, Inc.
MOUNTAIN VIEW, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy,...
NeuroPace Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
November 12, 2024 16:05 ET
|
NeuroPace, Inc.
-- Grew revenue 28% year-over-year to $21.1 million in Q3 2024 -- -- Increased full-year 2024 revenue guidance to $78 million to $80 million -- -- Demonstrated continued operating discipline through...
NeuroPace Announces FDA Submission of Three-Year Data from Post-Approval Study of the RNS System in Focal Epilepsy
November 04, 2024 16:05 ET
|
NeuroPace, Inc.
The RNS System Post-Approval Study (PAS) is the largest prospective post-approval study in neuromodulation for patients with drug-resistant focal epilepsy The RNS System PAS evaluates safety and...
NeuroPace to Report Third Quarter 2024 Financial Results on November 12, 2024
October 22, 2024 16:05 ET
|
NeuroPace, Inc.
MOUNTAIN VIEW, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it...
NeuroPace Continues to Strengthen Management Team
October 16, 2024 16:05 ET
|
NeuroPace, Inc.
MOUNTAIN VIEW, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced...
NeuroPace Strengthens Management Team with Two Key Appointments
September 04, 2024 16:05 ET
|
NeuroPace, Inc.
Appointed former key developer of RNS System as new Vice President of Research and Development Appointed former head of commercial marketing for Boston Scientific’s DBS franchise as the new Vice...
NeuroPace Announces Participation at Two Upcoming Healthcare Investor Conferences
August 27, 2024 16:05 ET
|
NeuroPace, Inc.
MOUNTAIN VIEW, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it...